Rare Pediatric Disease Priority Review Voucher (PRV) granted by FDA at approval to be transferred from Sentynl Therapeutics to Cyprium Cyprium eligible to receive tiered royalties and up to $129 million in aggregate development and sales milestones from Sentynl Therapeutics MIAMI, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that the U.S. Food and Drug Administration (“FDA”) has ...

Core Insights - Rocket Pharmaceuticals (RCKT) has had its resubmitted biologics license application (BLA) for gene therapy Kresladi accepted by the FDA, aiming to treat severe leukocyte adhesion deficiency-I (LAD-I) [1][7] - The FDA's decision on the BLA is anticipated by March 28, 2026, with the potential approval marking RCKT's first commercial product [1][10] - Following the announcement, RCKT's shares increased by 23.1% [1] Company Performance - Year-to-date, RCKT's shares have decreased by 66.1%, contrasting with a 7.7% increase in the industry [4] Clinical Data - The BLA is supported by positive results from a global phase I/II study, demonstrating 100% overall survival for LAD-I patients at 12 months post-infusion, meeting all primary and secondary endpoints [2] - Kresladi treatment was well tolerated, with no serious adverse effects reported [2] Regulatory Incentives - If approved, RCKT will qualify for a Rare Pediatric Disease Priority Review Voucher (PRV), which can expedite the approval of another drug or be sold to a larger pharmaceutical company [3] Background on LAD-I - LAD-I is a rare genetic disorder caused by a defect in the ITGB2 gene, leading to severe immune system issues and recurrent infections [9]